Abnormal karyotypes in patients with NPM1-mutated from GIMEMA/EORTC
| . | Code Pt . | Karyotype . | MRC . | MLD . |
|---|---|---|---|---|
| 1 | 479A/09 | 46,XX,del(9)(q22)[3]/46,XX[17] | + | + |
| 2 | 382A/04 | 44–45,X,−Y,−22[cp7]/46,XY[12] | − | − |
| 3 | 04A31 | 43–45,XY,−7/46,XY,del(7)(q?)/46,XY | + | − |
| 4 | 19 158 | 46,XX,inv(3)(q21q26)*[2]/46,XX[19] | − | − |
| 5 | 548A/19 | 35–44,−X,−6,−8,−19[7]/46,XY[7] | + | − |
| 6 | 19909 | 79–163<3n>XXXYYY[14]/ 46,XY[6] | + | − |
| 7 | 248A/24 | 45,XY,−21[3]/46,XY[17] | − | − |
| 8 | 24922 | 47,XX,+8,add(18)(q23)[26]/46,XX[1] | − | − |
| 9 | 210A/28 | 47,XX,+8[10] | − | − |
| 10 | 742A/28 | 46,XX,t(10;17)(q26;q11),del(13)(q12q31)[5]/ 46,XX[10] | + | − |
| 11 | 276A/30 | 45,XY,del(11)(q13q23),−15[12]/46,XY[13] | + | − |
| 12 | 623A/85 | 45,X,−X[15] | − | − |
| . | Code Pt . | Karyotype . | MRC . | MLD . |
|---|---|---|---|---|
| 1 | 479A/09 | 46,XX,del(9)(q22)[3]/46,XX[17] | + | + |
| 2 | 382A/04 | 44–45,X,−Y,−22[cp7]/46,XY[12] | − | − |
| 3 | 04A31 | 43–45,XY,−7/46,XY,del(7)(q?)/46,XY | + | − |
| 4 | 19 158 | 46,XX,inv(3)(q21q26)*[2]/46,XX[19] | − | − |
| 5 | 548A/19 | 35–44,−X,−6,−8,−19[7]/46,XY[7] | + | − |
| 6 | 19909 | 79–163<3n>XXXYYY[14]/ 46,XY[6] | + | − |
| 7 | 248A/24 | 45,XY,−21[3]/46,XY[17] | − | − |
| 8 | 24922 | 47,XX,+8,add(18)(q23)[26]/46,XX[1] | − | − |
| 9 | 210A/28 | 47,XX,+8[10] | − | − |
| 10 | 742A/28 | 46,XX,t(10;17)(q26;q11),del(13)(q12q31)[5]/ 46,XX[10] | + | − |
| 11 | 276A/30 | 45,XY,del(11)(q13q23),−15[12]/46,XY[13] | + | − |
| 12 | 623A/85 | 45,X,−X[15] | − | − |
MRC (myelodysplasia-related change) indicates which cases show cytogenetic abnormalities sufficient to diagnose acute myeloid leukemia (AML) with myelodysplasia-related features (according to World Health Organization [WHO] 200813 ); and MLD, cases with multilineage dysplasia (according to WHO 200813 ).
Probable inv(3) (difficult interpretation because of too few suboptimal metaphases).